News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiaGenic ASA Provides Update on Key Clinical Programs


7/29/2013 10:10:11 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) announces that the validation study for MCItect®, a blood based diagnostic test for Alzheimer’s disease in the pre-dementia stage, has failed to reach the study goals. Consequently, DiaGenic will not pursue CE-marking or U.S. trials with the current version of MCItect®. The clinical study for the company’s other key product AMYtect™ has successfully recruited 100 patients and will enter the analysis phase in August. In the development of MCItect®, DiaGenic reported results on July 17th 2012 from a 60-patient study demonstrating a total prediction accuracy of 74% in detecting patients converting from mild cognitive impairment to Alzheimer’s disease dementia. Utilizing an improved assay methodology and instrumentation, a separate non-overlapping subset of genes increased the prediction accuracy to 81%.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES